On the other hand, the infiltration of CCR7+ immune cells in tumor mesenchyme was promoted by VEGF-C administration, which increased the efficacy of anti-PD-1 immunotherapy in HCC mouse models (Fig. 7). The gene discussed is VEGFC; the disease is hepatocellular carcinoma.